

## **OptiNose to Present at Nasal and Respiratory Drug Delivery Conferences**

March 19, 2015 11:21 AM ET

**YARDLEY, PA, March 19, 2015**— OptiNose today announced that the company will present at the 2015 *Annual International Nasal Drug Delivery (NDD) Conference – Advances in Drug Therapies, Systemic Delivery and Device Technologies* in London, United Kingdom. They have also been invited to present at the 10<sup>th</sup> *Annual Respiratory Drug Delivery Conference – RDD Europe 2015* in Antibes, France.

Per Djupesland, MD, PhD, Founder and Chief Scientific Officer, will present new findings to support "Why Deposition Site Matters in Nasal Drug Delivery" at the NDD conference in April. He has also been invited to present on the topic of "Nose-to-Brain Transport – Opportunities and Challenges" at the RDD Europe Conference in May.

"We are extremely excited about the future of OptiNose and the significant milestones that our company expects to achieve in 2015 and beyond," Djupesland stated. "We continue to build on a strong pipeline of products that are being developed to leverage the advantages this unique new form of nasal drug delivery presents for treating serious diseases such as Migraine, Chronic Nasal Inflammatory Diseases and Autism Spectrum Disorders."

To learn more about the NDD conference, please visit: [www.management-forum.co.uk/medical-devices/events/nasal-drug-delivery-annual-international-conference/](http://www.management-forum.co.uk/medical-devices/events/nasal-drug-delivery-annual-international-conference/) and for the RDD Europe 2015 conference please visit: [www.rddonline.com](http://www.rddonline.com)

### **About OptiNose**

OptiNose is a Specialty Pharmaceutical Company developing a promising pipeline of late stage new products. The Company's patented Bi-Directional™ Breath Powered™ technology platform creates differentiated treatments by enabling deep intranasal drug deposition. OptiNose successfully out-licensed a first product at the end of phase 3 (AVP-825 for Migraine, licensed to AVNR in North America), and has proven clinical success with other products, including OPN-375, a treatment for Chronic Nasal Inflammatory Diseases (CNID) that will soon complete Phase 3. OPN-375 has the potential to be a breakthrough that creates a new standard of care for the treatment of serious CNID, such as Chronic Sinusitis or Recurrent Sinusitis. Other OptiNose pipeline products also target large and attractive markets with significant unmet need, including nose-to-brain technology applications such as OPN-300 for Autism. OptiNose has corporate offices in the US, Norway and the UK.

### **About OptiNose's Bi-Directional™ Breath Powered™ Delivery Technology**

OptiNose's patented closed-palate Bi-Directional Breath Powered delivery technology is unique in that it uses the natural function of a user's breath to propel medications beyond the nasal valve into the deep, targeted areas of the nasal cavity more effectively and efficiently than current treatment approaches. A user exhales into the device, creating a natural closure of the soft palate and sealing off the nasal cavity completely. The exhaled breath carries medication from the device into one side of the nose through a specially shaped sealing nosepiece, balancing the pressure on the soft palate. Narrow nasal passages are gently expanded and medication is transported well beyond the nasal valve to targeted sites. After delivering medication to the targeted sites, air flows around to the opposite side of the nasal cavity and exits through the other side of the nose rather than into the throat or lungs.

### **Contacts**

OptiNose Media Contact

Sloane & Company

Kate Traynor

212-446-1871

[Ktraynor@sloanepr.com](mailto:Ktraynor@sloanepr.com)